You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The cancer therapy developer has asked a US federal court to declare that its Illuminox platform does not infringe Illumina's trademarks.
According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.
Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics.
Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK.
Antibody products manufactured by Bethyl will be verified on Fluidigm's Hyperion imaging system and subsequently offered to Fluidigm's customers.
The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
According to the Atlantic, the Centers for Disease Control and Prevention and several US states are combining viral and antibody testing data for SARS-CoV-2, making that data hard to parse.
The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.
Olink Proteomics' proximity extension assay technology uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.